Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Acute blood biomarkers predict chronic insomnia trajectories following traumatic brain injury: A TRACK-TBI study
Sleep
S1 - Sleep: Want to Hear the Latest? (2:00 PM-2:12 PM)
006

Approximately 50% of individuals who sustain a TBI develop chronic insomnia, with known deleterious consequences. The underlying physiologies and temporal trajectories associated with TBI-related insomnia are unknown.

To examine the relation between acute biomarkers of neuronal injury and trajectories of insomnia following traumatic brain injury (TBI)

Blood biomarkers (GFAP, UCHL1, hsCRP) and self-reported insomnia symptoms were collected from 1700 patients enrolled in the FITBIR-standardized multi-center TRACK-TBI study. Biomarkers were collected at post-injury days 1 and 14 (D1, D14). Insomnia Severity Index (ISI) was scored at post-injury D14, months 3, 6, and 12. Unconditional latent class mixed models (LCMMs) were constructed to model distinct ISI trajectory classes. Multinomial logistic regression models evaluated whether acute biomarker levels could differentiate the identified trajectory classes after adjusting for age, sex, race, psychiatric history and CT status.

LCMMs yielded a best-fit model of 5 latent classes of ISI symptom trajectories (C1=sustained severe; C2=sustained mild; C3=mild deteriorating; C4=severe resolving; C5=mild resolving). Adjusted regression models demonstrated that higher GFAP and lower hsCRP at D1 and/or D14 were associated with increased likelihood of membership in a lower-severity ISI class. Specifically, D1 hsCRP significantly differentiated C1 versus C2 (OR=1.2 [1.02-1.42] per log unit decrease). Both D1 and D14 GFAP and hsCRP differentiated C1 versus C5 (D1 GFAP OR=1.39 [1.15-1.67] per log unit increase & hsCRP OR=1.37 [1.15-1.63] per log unit decrease; D14 GFAP OR=1.59 [1.09-2.33] per log unit increase & hsCRP OR=1.39 [1.09-1.72] per log unit decrease). D14 hsCRP additionally differentiated C1 from C4 (OR=1.43 [1.02-2.0] per log unit decrease). UCHL1 levels were not significantly associated with trajectory likelihood.

Following TBI, acute levels of GFAP and hsCRP predict trajectories of insomnia symptoms, including persistent severe insomnia. Future studies are needed to examine the underlying mechanisms and clinical implications of these associations.

Authors/Disclosures
J. Kent Werner, Jr., MD, PhD (Uniformed Services University)
PRESENTER
Dr. Werner has received personal compensation for serving as an employee of Cogentis Therapeutics. Dr. Werner has stock in Cogentis Therapeutics. Dr. Werner has received intellectual property interests from a discovery or technology relating to health care. Dr. Werner has received intellectual property interests from a discovery or technology relating to health care. Dr. Werner has received personal compensation in the range of $100,000-$499,999 for serving as a Neurologist with United States Navy. Dr. Werner has received personal compensation in the range of $50,000-$99,999 for serving as a CEO / CoFounder with Cogentis Therapeutics.
No disclosure on file
Bryson Hewins Mr. Hewins has nothing to disclose.
Andrew Krystal No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Joseph T. Giacino, PhD Dr. Giacino has nothing to disclose.
Raquel Gardner, MD (Sheba Medical Center) Dr. Gardner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BrainBox. The institution of Dr. Gardner has received research support from NIH. The institution of Dr. Gardner has received research support from DoD.
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Ramon R. Diaz-Arrastia, MD, PhD, FAAN (University of Pennsylvania) Dr. Diaz-Arrastia has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ischemix, Inc. Dr. Diaz-Arrastia has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pinteon Therapeutics. Dr. Diaz-Arrastia has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BrainBox, LLC. Dr. Diaz-Arrastia has received stock or an ownership interest from BrainBox, LLC. Dr. Diaz-Arrastia has received stock or an ownership interest from NovaSignal . Dr. Diaz-Arrastia has received stock or an ownership interest from Nia Therpeutics. The institution of Dr. Diaz-Arrastia has received research support from National Institutes of Health. The institution of Dr. Diaz-Arrastia has received research support from Department of Defense.
Geoffrey Manley, MD, PhD (UCSF Med Ctr/Dept of Neurosurgery) The institution of Dr. Manley has received research support from NIH-NINDS. The institution of Dr. Manley has received research support from US Department of Defense. The institution of Dr. Manley has received research support from US Department of Defense/MTEC. The institution of Dr. Manley has received research support from One Mind. The institution of Dr. Manley has received research support from Neurotrauma Sciences, LLC. The institution of Dr. Manley has received research support from NFL Scientific Advisory Board.
No disclosure on file